733 related articles for article (PubMed ID: 20185460)
1. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
[TBL] [Abstract][Full Text] [Related]
2. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
[TBL] [Abstract][Full Text] [Related]
3. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
4. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
[TBL] [Abstract][Full Text] [Related]
5. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH
N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301
[TBL] [Abstract][Full Text] [Related]
7. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Jourdan E; Rigal-Huguet F; Marit G; Vey N; Dastugue N; Fegueux N; Molina L; Gastaut JA; Legros L; Zerazhi H; Cailleres S; Bauduer F; Bordessoule D; Attal M; Blaise D; Pigneux A;
Br J Haematol; 2005 May; 129(3):403-10. PubMed ID: 15842665
[TBL] [Abstract][Full Text] [Related]
8. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM
Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
10. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
11. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
[TBL] [Abstract][Full Text] [Related]
13. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
15. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
[TBL] [Abstract][Full Text] [Related]
16. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
17. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
[TBL] [Abstract][Full Text] [Related]
18. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
19. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
20. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
